Prevention of central nervous system relapses in diffuse large B-cell lymphoma
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference16 articles.
1. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.;Herrlinger;Semin Oncol,2009
2. Incidence and risk factors of central nervous system recurrence in aggressive lymphomaa survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL).;Boehme;Ann Oncol,2007
3. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.;Feugier;Ann Oncol,2004
4. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).;Boehme;Blood,2009
5. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkins lymphoma patients at high risk of central nervous system disease in the rituximab era.;Sancho;Eur J Haematol,2010
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Addition of low dose acetazolamide as an adjunct in patients undergoing high dose methotrexate is safe and beneficial;Internal Medicine Journal;2020-03
2. Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma;Cancer Chemotherapy and Pharmacology;2019-12-17
3. Lymphome des Zentralnervensystems;Pathologie;2018-10-30
4. The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis;Leukemia & Lymphoma;2017-06-08
5. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial;Annals of Hematology;2016-03-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3